60.2 Parkinson's Disease & Essential Tremor

ABFM Family Medicine Certification Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Structure, Blueprint & Clinical Decision-Making

1.1 Exam Blueprint, FMCLA vs. One-Day Exam & Board Scoring 1.2 Clinical Reasoning, Test-Taking Strategy & Ambiguity Management 1.3 Evidence-Based Medicine & Clinical Practice Guidelines in Primary Care

2 Chapter 2: Healthcare Systems, Practice Management & Quality

2.1 Practice Management, Billing, Coding & Documentation 2.2 Quality Improvement, Patient Safety & Diagnostic Stewardship 2.3 Interprofessional Team-Based Care & Care Coordination

3 Chapter 3: Ethics, Law, Biostatistics & Health Equity

3.1 Medical Ethics, Informed Consent & Surrogate Decision-Making 3.2 Biostatistics, Clinical Epidemiology & Diagnostic Test Interpretation 3.3 Social Determinants of Health, Health Equity & Cultural Humility 3.4 Physician Wellness, Burnout Prevention & Professionalism

4 Chapter 4: Lifestyle Counseling & Behavior Change

4.1 Alcohol Use Screening & Brief Intervention 4.2 Illicit Drug & Cannabis Counseling 4.3 Tobacco & Vaping Cessation Counseling

5 Chapter 5: Nutrition, Physical Activity & Chronic Disease Prevention

5.1 Dietary Counseling for Obesity & Chronic Disease Prevention 5.2 Exercise Prescription & Physical Activity Counseling 5.3 Genetic Risk Assessment & Family History Counseling

6 Chapter 6: Routine Adult Immunizations

6.1 ACIP Adult Respiratory Vaccines: Influenza, COVID-19, RSV & Pneumococcal 6.2 ACIP Adult Non-Respiratory Vaccines: Tdap, Shingrix, HPV & Hep B 6.3 Immunizations in Special Populations: Pregnancy, Asplenia & Immunocompromise

7 Chapter 7: Pediatric Health Maintenance & Surveillance

7.1 Newborn Examination & Early Postnatal Care 7.2 Well-Child Care, Developmental Surveillance & Milestones 7.3 Pediatric & Adolescent Screening: Vision, Hearing, Anemia & Lead 7.4 Pediatric Oral Health, Dental Screening & Fluoride

8 Chapter 8: Behavioral Health & Safety Screening

8.1 Primary Care Depression, Anxiety & Behavioral Health Screening 8.2 Domestic Violence, Intimate Partner Violence & Firearm Safety 8.3 Occupational Health & Recreational Safety Counseling

9 Chapter 9: Adult Preventive Screening: Cardiovascular & Metabolic

9.1 Cardiovascular Disease & Hypertension Screening 9.2 Type 2 Diabetes Screening & Prediabetes Risk Stratification 9.3 Abdominal Aortic Aneurysm & Osteoporosis Screening

10 Chapter 10: Adult Cancer Screening: Breast & Gynecologic

10.1 Breast Cancer Screening & Risk-Assessment 10.2 Cervical Cancer Screening & ASCCP Algorithms 10.3 Skin Cancer Clinical Assessment & Counseling

11 Chapter 11: Adult Cancer Screening: Colorectal, Lung & Prostate

11.1 Colorectal Cancer Screening Modalities & Intervals 11.2 Lung Cancer Screening with Low-Dose CT 11.3 Prostate Cancer Screening & Shared Decision-Making

12 Chapter 12: Sexual Health, Infectious Disease Screening & Contraception

12.1 Sexual Health Counseling & Risk-Reduction Strategies 12.2 STI Screening: Chlamydia, Gonorrhea, Syphilis & Trichomoniasis 12.3 Bloodborne Infectious Disease Screening: HIV & Hepatitis C

13 Chapter 13: Reproductive Life Planning, Lactation & Preoperative Care

13.1 Preconception Planning & Comprehensive Contraception Management 13.2 Lactation Support & Breastfeeding Counseling 13.3 Preoperative Medical Evaluation & Pre-Participation Sports Exam

14 Chapter 14: Emergent Cardiovascular Conditions

14.1 Acute Coronary Syndromes & Myocardial Infarction 14.2 Acute Chest Pain Risk Stratification & Triage 14.3 Acute or Critical Valvular Heart Emergencies

15 Chapter 15: Cardiac Arrhythmias, Heart Failure & Hypertensive Crises

15.1 Acute Atrial & Ventricular Arrhythmias 15.2 Acute Decompensated Heart Failure & Cardiogenic Shock 15.3 Hypertensive Emergency & Urgency Management

16 Chapter 16: Vascular & Thromboembolic Emergencies

16.1 Pulmonary Embolism & Deep Vein Thrombosis 16.2 Acute Aortic Syndromes & Peripheral Vascular Emergencies 16.3 Critical Limb Ischemia & Acute Arterial Occlusion

17 Chapter 17: Neurologic Emergencies: Stroke & Altered Consciousness

17.1 Acute Ischemic Stroke & Intracranial Hemorrhage 17.2 Syncope Evaluation & Status Epilepticus 17.3 Acute Delirium, Encephalopathy & Severe Confusion

18 Chapter 18: Neurologic Trauma & Acute Cranial Emergencies

18.1 Concussion, Moderate-to-Severe TBI & Intracranial Injury 18.2 Thunderclap & Acute Severe Secondary Headaches 18.3 Acute Ophthalmologic Emergencies

19 Chapter 19: Acute Abdominal, Pelvic & Gastrointestinal Emergencies

19.1 Acute Abdominal & Pelvic Pain Triage 19.2 Upper & Lower Gastrointestinal Bleeding 19.3 Acute Hepatic Failure, Cholangitis & Severe Jaundice

20 Chapter 20: Acute Pulmonary & Airway Emergencies

20.1 Acute Hypoxic Respiratory Failure & ARDS 20.2 Severe Community-Acquired Pneumonia & Empyema 20.3 Acute Severe Epistaxis & Airway Obstruction

21 Chapter 21: Acute Traumatic Injuries & Wound Care

21.1 Major Trauma Resuscitation & Initial Assessment 21.2 Burn Assessment, Inhalation Injury & Resuscitation 21.3 Laceration Management, Complex Wounds & Animal Bites

22 Chapter 22: Acute Orthopedic & Musculoskeletal Emergencies

22.1 Acute Ambulatory Fractures & Initial Splinting 22.2 Compartment Syndrome & Major Orthopedic Trauma 22.3 Septic Arthritis & Acute Microcrystalline Crises

23 Chapter 23: Severe Infections, Sepsis & Systemic Emergencies

23.1 Sepsis, Septic Shock & Initial Fluid Resuscitation 23.2 Necrotizing Soft Tissue Infections & Severe CNS Infections 23.3 Anaphylaxis Diagnosis, Epinephrine Dosing & Airway Protection

24 Chapter 24: Metabolic, Endocrine & Electrolyte Emergencies

24.1 Diabetic Ketoacidosis & Hyperosmolar Hyperglycemic State 24.2 Critical Electrolyte Emergencies: Dyskalemias & Dysnatremias 24.3 Severe Calcium Abnormalities & Acute Adrenal Crisis

25 Chapter 25: Hematologic, Urologic & Dental Emergencies

25.1 Severe Symptomatic Anemias & Coagulopathic Emergencies 25.2 Testicular Torsion, Priapism & Acute Urinary Retention 25.3 Urgent Odontogenic Infections & Dental Trauma

26 Chapter 26: Psychiatric, Behavioral & Obstetric/Gynecologic Emergencies

26.1 Suicidal Ideation, Acute Agitation & Behavioral Emergencies 26.2 Acute Physical & Sexual Assault Care 26.3 Life-Threatening Vaginal Bleeding & Ectopic Pregnancy 26.4 Environmental Heat Stroke & Severe Hypothermia

27 Chapter 27: Acute Head, Neck & Neurologic Symptoms

27.1 Primary Acute Headaches: Migraine, Tension & Cluster 27.2 Concussion & Minor Closed Head Injury Evaluation 27.3 Transient Ischemic Attack Evaluation & ABCD2 Risk Scoring

28 Chapter 28: Acute Cranial Nerves, Hearing & Sensory Symptoms

28.1 Peripheral Neuropathies: Bell's Palsy, Carpal Tunnel & Radiculopathy 28.2 Acute Tinnitus, Sudden Sensorineural Hearing Loss & Cerumen Impaction 28.3 Acute Dizziness, Benign Paroxysmal Positional Vertigo & Vestibular Neuritis

29 Chapter 29: Acute Upper Respiratory Tract Infections

29.1 Acute Viral Rhinosinusitis vs. Bacterial Rhinosinusitis 29.2 Acute Pharyngitis: Group A Streptococcus & Centor Criteria 29.3 Acute Otitis Media, Otitis Externa & Serous Effusion

30 Chapter 30: Acute Lower Respiratory Infections & Cough

30.1 Influenza, COVID-19 & Viral Respiratory Syndromes 30.2 Acute Bronchitis & Lower Respiratory Tract Infections 30.3 Ambulatory Community-Acquired Pneumonia

31 Chapter 31: Allergic, Nasal & Non-Infectious Pulmonary Conditions

31.1 Allergic Rhinitis & Acute Non-Anaphylactic Allergic Reactions 31.2 Acute Dyspnea in Ambulatory Care 31.3 Interstitial Lung Diseases & Sarcoidosis Presentation

32 Chapter 32: Acute Chest, Cardiac & Vascular Symptoms

32.1 Palpitations Evaluation & Arrhythmia Triage in Primary Care 32.2 Deep Vein Thrombosis & Superficial Thrombophlebitis 32.3 Ambulatory Hypotension & Orthostasis Evaluation

33 Chapter 33: Acute Upper Gastrointestinal Conditions

33.1 Peptic Ulcer Disease & Gastritis 33.2 Dysphagia, Esophagitis & Acute Esophageal Disorders 33.3 Acute Nausea, Vomiting & Foodborne Illness

34 Chapter 34: Acute Lower Gastrointestinal Conditions

34.1 Acute Infectious Diarrhea & Gastroenteritis 34.2 Acute Constipation & Functional Bowel Changes 34.3 Ano-Rectal Disorders: Hemorrhoids, Fissures, Abscesses & Pruritus Ani

35 Chapter 35: Inflammatory, Functional & Malabsorptive GI Disorders

35.1 Acute Flares of Inflammatory Bowel Disease 35.2 Irritable Bowel Syndrome: Diagnosis, Subtyping & Management 35.3 Celiac Disease & Malabsorption Syndromes

36 Chapter 36: Acute Abdominal, Hepatic & Biliary Disorders

36.1 Ambulatory Abdominal & Pelvic Pain Triage 36.2 Acute Cholecystitis, Biliary Colic & Pancreatitis 36.3 Acute Liver Injury & Viral Hepatitis

37 Chapter 37: Acute Abdominal Wall, Hernias & Dental Conditions

37.1 Abdominal Wall, Inguinal & Ventral Hernias 37.2 Acute Dental Pain, Odontogenic Abscess & Aphthous Ulcers 37.3 Acute Edema: Unilateral vs. Bilateral Diagnostic Evaluation

38 Chapter 38: Acute Infectious Dermatoses

38.1 Bacterial Skin Infections: Impetigo, Cellulitis & Cutaneous Abscesses 38.2 Fungal Skin Infections: Tinea Corporis, Cruris, Pedis & Onychomycosis 38.3 Viral Cutaneous Infections: Herpes Simplex, Zoster & Molluscum Contagiosum

39 Chapter 39: Inflammatory, Allergic & Autoimmune Dermatoses

39.1 Atopic Dermatitis, Contact Dermatitis & Eczematous Flares 39.2 Non-Infectious Rashes: Urticaria, Drug Eruptions & Erythema Multiforme 39.3 Cutaneous Malignancies & Premalignant Lesions: AK, BCC, SCC & Melanoma

40 Chapter 40: Acute Shoulder, Elbow & Upper Extremity Injuries

40.1 Rotator Cuff Pathology, Tendinopathy & Shoulder Impingement 40.2 Lateral & Medial Epicondylitis, Olecranon Bursitis & Elbow Sprains 40.3 Wrist & Hand Soft-Tissue Injuries: De Quervain, TFCC & Finger Sprains

41 Chapter 41: Acute Knee, Ankle & Lower Extremity Injuries

41.1 Meniscal Tears, Ligamentous Knee Injuries & Patellofemoral Pain 41.2 Ankle Sprains, Ottawa Ankle Rules & Achilles Tendinopathy 41.3 Plantar Fasciitis, Shin Splints & Overuse Syndromes

42 Chapter 42: Acute Ambulatory Fractures & Dislocations

42.1 Distal Radius, Scaphoid & Common Upper Extremity Fractures 42.2 Metatarsal, Clavicle & Common Lower Extremity Fractures 42.3 Joint Dislocation Management: Nursemaid's Elbow & Shoulder Subluxation

43 Chapter 43: Acute Axial Musculoskeletal Pain & Falls

43.1 Acute Low Back Pain: Red Flags, Strain & Disc Herniation 43.2 Acute Cervical Strain, Whiplash & Axial Neck Pain 43.3 Evaluation of Falls in Ambulatory & Older Patients

44 Chapter 44: Acute Inflammatory Arthropathies & Generalized Pain

44.1 Acute Inflammatory Arthritis & Spondyloarthropathies 44.2 Myalgias, Rhabdomyolysis & Post-Viral Pain Syndromes 44.3 Acute Non-Headache Pain Management Strategies

45 Chapter 45: Acute Renal, Urinary & Genitourinary Conditions

45.1 Uncomplicated UTI, Pyelonephritis & Acute Urethritis 45.2 Hematuria Workup & Glomerulonephritis 45.3 Nephrolithiasis & Acute Urinary Tract Obstruction

46 Chapter 46: Acute Male Genitourinary & Prostatic Conditions

46.1 Acute Prostatitis, Epididymitis & Orchitis 46.2 Acute Scrotal Pain: Torsion vs Appendage, BPH & Male Genital Emergencies 46.3 Acute Urinary Retention & Incontinence Evaluation

47 Chapter 47: Acute Women's Health & Early Pregnancy Care

47.1 Early Pregnancy Diagnosis, Dating & Initial Complications 47.2 Abnormal Uterine Bleeding & Acute Menstrual Disorders 47.3 Premenstrual Syndrome & Premenstrual Dysphoric Disorder

48 Chapter 48: Breast Disorders, STIs & Pediatric Elimination

48.1 Palpable Breast Mass, Mastitis & Nipple Discharge 48.2 Sexually Transmitted Infections: Diagnosis, Staging & CDC Guidelines 48.3 Pediatric Enuresis & Encopresis

49 Chapter 49: Systemic Signs, Metabolic Dysregulation & Miscellaneous Infections

49.1 Acute Fever, Sepsis Screening & FUO in Primary Care 49.2 Acute Hyperglycemia & Symptomatic Hypoglycemia 49.3 Electrolyte Abnormalities: Mild-to-Moderate Disturbances 49.4 Vector-Borne, Tick-Borne & Rickettsial Illnesses

50 Chapter 50: Chronic Cardiovascular Diseases: Hypertension & Ischemia

50.1 Essential Hypertension Management: 2025 AHA/ACC Guideline & JNC Strategies 50.2 Chronic Coronary Artery Disease & Post-MI Secondary Prevention 50.3 Chronic Heart Failure: HFrEF, HFpEF & Quadruple GDMT

51 Chapter 51: Chronic Vascular, Valvular & Dyslipidemic Diseases

51.1 Peripheral Arterial Disease & Claudication 51.2 Chronic Valvular Heart Disease & Murmur Evaluation 51.3 Lipid Disorders & ASCVD Risk-Based Statin Therapy

52 Chapter 52: Chronic Respiratory Diseases: Asthma & COPD

52.1 Chronic Asthma Management: GINA Stepwise SMART Therapy 52.2 Chronic Obstructive Pulmonary Disease: GOLD Recommendations 52.3 Solitary Pulmonary Nodule Evaluation & Fleischner Society Criteria

53 Chapter 53: Chronic Metabolic Diseases: Diabetes Mellitus

53.1 Type 2 Diabetes Management: ADA Pharmacotherapy Algorithms 53.2 Type 1 Diabetes: Basal-Bolus Insulin, CGMs & Diabetic Complications 53.3 Diabetic Microvascular & Macrovascular Disease Surveillance

54 Chapter 54: Obesity, Nutrition & Metabolic Bone Diseases

54.1 Medical & Behavioral Management of Obesity & Incretin Mimetics 54.2 Osteoporosis & Metabolic Bone Disease: DEXA, FRAX & Antiresorptives 54.3 Nutritional Deficiencies: Vitamin D, B12, Iron & Malnutrition

55 Chapter 55: Chronic Endocrine Disorders

55.1 Primary & Subclinical Hypothyroidism, Hyperthyroidism & Nodules 55.2 Adrenal Disorders: Addison's Disease & Cushing's Syndrome 55.3 Hypercalcemia, Hyperparathyroidism & Pituitary Disorders

56 Chapter 56: Chronic Kidney Disease & Venous Disorders

56.1 Chronic Kidney Disease: KDIGO Staging & Renoprotective Therapy 56.2 Chronic Venous Insufficiency, Stasis Dermatitis & Lymphedema 56.3 Chronic Electrolyte & Acid-Base Management in CKD

57 Chapter 57: Chronic Gastrointestinal & Hepatic Diseases

57.1 Gastroesophageal Reflux Disease, Barrett's Esophagus & Dyspepsia 57.2 Chronic Liver Disease: MASLD/NAFLD, Cirrhosis & Portal Hypertension 57.3 Viral Hepatitis B & C: Long-Term Monitoring & DAA Therapy

58 Chapter 58: Colorectal Surveillance & Chronic Pancreaticobiliary Care

58.1 Post-Polypectomy Colorectal Polyp Surveillance Guidelines 58.2 Chronic Pancreatitis & Exocrine Pancreatic Insufficiency 58.3 Chronic Nausea, Gastroparesis & Functional GI Disorders

59 Chapter 59: Chronic Musculoskeletal & Rheumatologic Disorders

59.1 Osteoarthritis: Hip, Knee & Hand Management 59.2 Spinal Conditions: Spinal Stenosis, Spondylolisthesis & Compression Fractures 59.3 Chronic Myopathies & Fibromyalgia Syndrome

60 Chapter 60: Chronic Neurologic & Neurodegenerative Disorders

60.1 Dementia: Alzheimer's, Vascular & Lewy Body Disease 60.2 Parkinson's Disease & Essential Tremor 60.3 Epilepsy: Chronic Antiseizure Medications & Post-Stroke Care

61 Chapter 61: Chronic Peripheral Nerves, Pain & Sensory Disorders

61.1 Diabetic & Chronic Peripheral Neuropathies 61.2 Chronic Pain Syndromes & Chronic Daily Headaches 61.3 Chronic Tinnitus, Presbycusis & Persistent Dizziness

62 Chapter 62: Chronic Psychiatric Disorders

62.1 Major Depressive Disorder & Generalized Anxiety Disorder 62.2 Bipolar Disorder: Maintenance Pharmacotherapy & Lithium Monitoring 62.3 Adult & Pediatric Attention-Deficit/Hyperactivity Disorder

63 Chapter 63: Chronic Behavioral Health & Neurodevelopmental Conditions

63.1 Chronic Behavioral Conditions: PTSD, OCD & Somatization 63.2 Autism Spectrum Disorder & Intellectual Disabilities 63.3 Eating Disorders: Anorexia Nervosa, Bulimia & Binge Eating

64 Chapter 64: Chronic Substance Use Disorders & Tobacco Cessation

64.1 Alcohol Use Disorder: Pharmacotherapy & Relapse Prevention 64.2 Opioid & Stimulant Use Disorders: MOUD & Harm Reduction 64.3 Longitudinal Tobacco Cessation Pharmacotherapy

65 Chapter 65: Chronic Dermatologic Conditions

65.1 Acne Vulgaris, Rosacea & Seborrheic Dermatitis 65.2 Chronic Plaque Psoriasis & Biologic Therapies 65.3 Chronic Eczema, Hidradenitis Suppurativa & Cutaneous Lupus

66 Chapter 66: Chronic Reproductive, Infectious & Geriatric Special Care

66.1 Chronic Menstrual Disorders, Infertility & Sexual Dysfunction 66.2 Menopause Management & Hormone Replacement Therapy 66.3 Chronic HIV Infection Management & Primary Care Integration 66.4 Gender-Affirming Primary Care & Hormone Therapy 66.5 Advance Care Planning, Palliative Care & End-of-Life Symptom Control

67 Chapter 67: Continuity Care: Sleep, Fatigue, Cancer, Pregnancy & the Adult Preventive Visit

67.1 Chronic Insomnia & Obstructive Sleep Apnea 67.2 Chronic Malaise, Fatigue & ME/CFS 67.3 Primary Care During Cancer Treatment & Survivorship 67.4 Routine Prenatal Care & Longitudinal Pregnancy Management 67.5 The Periodic Adult Health Examination & Medicare Annual Wellness Visit

60.2 Parkinson's Disease & Essential Tremor

Key Takeaways Explain This Topic AI

Parkinson's disease (PD) is an alpha-synuclein neurodegenerative disorder characterized by loss of dopaminergic projection neurons in the substantia nigra pars compacta; clinical diagnosis requires bradykinesia plus at least one other cardinal feature: asymmetric 4-6 Hz resting tremor, cogwheel/lead-pipe rigidity, or postural instability (TRAP mnemonic).

Non-motor manifestations—including hyposmia/anosmia, chronic refractory constipation, REM sleep behavior disorder (RBD, dream enactment due to loss of muscle atonia), depression/anxiety, and orthostatic hypotension—frequently precede motor parkinsonism by 5 to 15 years.

Carbidopa/levodopa is the gold-standard symptomatic therapy; carbidopa is a peripheral dopa-decarboxylase inhibitor that does not cross the blood-brain barrier, preventing peripheral conversion of levodopa to dopamine and abolishing severe nausea, vomiting, and orthostasis; long-term therapy (>5 years) is complicated by 'wearing-off' motor fluctuations and peak-dose dyskinesias.

Non-ergot dopamine agonists (pramipexole, ropinirole, rotigotine) may be considered as initial monotherapy in younger patients (<60y) to delay motor fluctuations, but carry high risks of impulse control disorders (15-20% developing pathological gambling, hypersexuality, compulsive shopping), sudden daytime sleep attacks, and peripheral edema.

Essential tremor (ET) is the most common movement disorder, featuring an 8-12 Hz bilateral action and postural tremor (absent at rest, prominent during purposeful motor tasks and arms held outstretched against gravity), often autosomal dominant, involving hands, head (titubation), and voice while sparing the legs; temporary improvement with small amounts of alcohol is pathognomonic; first-line pharmacotherapy is propranolol or primidone.

Last updated: September 2026

Neurobiology & Cardinal Motor Manifestations of Parkinson's Disease

Parkinson's disease (PD) is the second most prevalent neurodegenerative disorder worldwide. The fundamental neuropathological hallmark is the progressive degeneration and loss of neuromelanin-containing dopaminergic projection neurons in the substantia nigra pars compacta (SNpc) that project to the dorsal striatum (caudate nucleus and putamen). By the time classical motor symptoms manifest, approximately 50% to 70% of nigrostriatal dopaminergic neurons have already undergone apoptotic degeneration , with an 80% depletion of striatal dopamine levels. The histological signature is the intracellular presence of Lewy bodies —abnormal cytoplasmic inclusions composed primarily of aggregated, misfolded alpha-synuclein protein. THE CARDINAL MOTOR MANIFESTATIONS (TRAP MNEMONIC)

Cardinal Sign Clinical Examination Features & Pathophysiology Distinguishing Diagnostic Clues
═════════════════════════════════════════════════════════════════════════════════════════════════════════════

Tremor (Resting) • 4 to 6 Hz low-frequency "pill-rolling" tremor. • Characteristically ASYMMETRIC onset (one hand).

• Present at complete rest, with the limb fully supported. • SUPPRESSED during purposeful movement.

• Re-emerges after a brief latency when holding a posture. • Does not involve the head (jaw/chin can shake).

─────────────────────────────────────────────────────────────────────────────────────────────────────────

Rigidity • Increased resistance to passive joint mobilization. • Resistance is velocity-INDEPENDENT (unlike spasticity).

• "Lead-pipe": uniform, smooth resistance throughout range. • Froment sign: rigidity accentuates when patient

• "Cogwheel": ratcheting resistance caused by superimposed performs voluntary movement with contralateral limb.

resting tremor oscillations on hypertonia.

─────────────────────────────────────────────────────────────────────────────────────────────────────────

Akinesia / • OBLIGATORY CRITERION: slowness of movement initiation • Progressive reduction in SPEED and AMPLITUDE

Bradykinesia with progressive fatigue and decrement during rapid during repetitive movements (finger tapping, toe taps).

repetitive movements. • Masked facies (hypomimia), reduced blink rate,

soft monotonous speech (hypophonia), micrographia.

─────────────────────────────────────────────────────────────────────────────────────────────────────────

Postural • Loss of normal postural corrective reflexes; retropulsion • LATE DISEASE FEATURE in idiopathic PD.

Instability elicited on the backward pull test. • If prominent within first 1-2 years, strongly

Frequent unprovoked falls; inability to recover balance. suspect Progressive Supranuclear Palsy (PSP).

═════════════════════════════════════════════════════════════════════════════════════════════════════════════
Additional Motor Signs

Shuffling, Festinating Gait : The patient ambulates with narrow-based, short, flat-footed shuffling steps. The center of gravity leans forward (propulsion/stooped posture), causing the steps to become progressively faster as if chasing the center of gravity (festination), culminating in freezing of gait.

En Bloc Turning : Turning requires multiple small, tentative steps (5 to 20 steps to turn 180 degrees) rather than a smooth, single-pivot motion.

Asymmetric Decreased Arm Swing : One of the earliest physical signs; the affected arm remains immobile or tucked against the flank during ambulation.

Micrographia : Handwriting starts at normal size but becomes progressively cramped, minuscule, and illegible across the page.

Non-Motor Features & Prodromal Parkinsonian Neurodegeneration

Under the Braak staging hypothesis , alpha-synuclein pathology does not originate in the substantia nigra. Instead, Lewy pathology begins years to decades earlier in the peripheral autonomic nervous system (enteric plexus) and the lower brainstem (dorsal motor nucleus of the vagus nerve) and olfactory bulb (Braak stages 1-2), before ascending through the midbrain (stages 3-4) and finally infiltrating the neocortex (stages 5-6). Consequently, non-motor symptoms precede the onset of motor parkinsonism by 5 to 20 years :

Hyposmia / Anosmia : Present in >90% of idiopathic PD patients; profound loss of olfactory discrimination occurs years before tremor or bradykinesia.

REM Sleep Behavior Disorder (RBD) : Degeneration of pontine inhibitory sublaterodorsal nuclei causes loss of normal physiological muscle atonia during REM sleep. Patients physically act out vivid, frightening dreams (punching, thrashing, vocalizing). Over 80% of individuals with idiopathic RBD convert to an overt alpha-synucleinopathy (PD, DLB, or MSA) within 10 to 15 years.

Chronic Constipation : Enteric nervous system Lewy body deposition results in profound colonic hypomotility, often present for decades before motor symptoms.

Neuropsychiatric Disturbances : Major depressive disorder and generalized anxiety occur in approximately 40% of patients due to early loss of ascending serotonergic (raphe nuclei) and noradrenergic (locus coeruleus) projections.

Autonomic Failure : Orthostatic hypotension (drop in SBP >=20 mmHg or DBP >=10 mmHg within 3 minutes of standing), neurogenic bladder (urinary urgency and frequency), and erectile dysfunction.

Sialorrhea : Excessive drooling resulting from impaired automatic swallowing mechanics rather than salivary hypersecretion.

Clinical Diagnosis & Differential Diagnosis of Atypical Parkinsonian Syndromes

The diagnosis of Parkinson's disease remains fundamentally clinical. Under the Movement Disorder Society (MDS) clinical diagnostic criteria, diagnosis requires:

Core Criterion : Bradykinesia plus at least one of resting tremor or rigidity.

Supportive Criteria : Clear, dramatic, and sustained beneficial response to dopaminergic therapy; presence of levodopa-induced peak-dose dyskinesia; asymmetric onset; resting tremor of a limb; and documented olfactory loss.

Absence of Absolute Exclusion Criteria : Absence of cerebellar signs, supranuclear downward gaze palsy, diagnosis of behavioral variant frontotemporal dementia or primary progressive aphasia within the first 5 years, or exposure to dopamine receptor-blocking medications. PARKINSONISM: ATYPICAL & SECONDARY SYNDROMES

Syndrome Distinctive Clinical Hallmarks Diagnostic Clues & Neuroimaging

═════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════

Progressive Supranuclear • Early falls within first 12 months (axial instability). • Brain MRI shows midbrain tegmentum atrophy

Palsy (PSP) • Vertical SUPRANUCLEAR GAZE PALSY (impaired downward saccades). with preserved pons ("Hummingbird sign").

• Severe axial rigidity > appendicular; "surprised" stare. • Poor/transient response to levodopa.

─────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────

Multiple System • Early, profound AUTONOMIC FAILURE (severe orthostatic • Brain MRI shows pontine T2 cross-hyperintensity

Atrophy (MSA) hypotension, urinary incontinence or retention, ED). ("Hot cross bun sign") and putaminal rim slit.

• Striatonigral type (MSA-P): atypical parkinsonism. • Laryngeal stridor, cold violaceous hands.

• Cerebellar type (MSA-C): prominent cerebellar ataxia.

Corticobasal • Asymmetric cortical signs: alien limb phenomenon, limb • Asymmetric parietal and frontal cortical atrophy.

Degeneration (CBD) apraxia, cortical sensory loss (astereognosis), myoclonus. • Extremely poor levodopa response.

• Marked appendicular rigid dystonia.

Drug-Induced • Subacute, SYMMETRICAL onset of bradykinesia and rigidity. • Normal DaTscan (SPECT I-123 ioflupane shows

Parkinsonism (DIP) • Caused by D2 receptor antagonists: Antipsychotics (Halo- intact presynaptic dopamine transporters).

peridol, Risperidone), Antiemetics (Metoclopramide, • Resolves weeks to months after offending

Prochlorperazine, Promethazine). medication is discontinued.

Pharmacotherapy of Parkinson's Disease: Motor Symptoms & Complications

Pharmacological management aims to restore striatal dopaminergic neurotransmission. No current medication has proven neuroprotective or disease-modifying capabilities; therapy is strictly symptomatic. EVIDENCE-BASED PHARMACOTHERAPY FOR PARKINSON'S DISEASE

Class & Agent Mechanism of Action Initial / Target Dose Adverse Effects & High-Yield Pearls

Dopamine Precursor Exogenous dopamine precursor IR: 25/100 mg PO TID; • GOLD STANDARD for motor symptoms.

• Carbidopa / Levodopa (levodopa) coupled with titrate to 50/200 mg TID • Carbidopa blocks peripheral conversion;

(Sinemet) peripheral dopa-decarboxy- or higher as needed. requires >= 75-100 mg carbidopa daily

lase inhibitor (carbidopa). to prevent nausea/orthostasis.

• Dietary protein competes for gut absorption.

Non-Ergot Dopamine Direct stimulation of Pramipexole: 0.125 mg TID up to • Preferred in younger patients (<60y) to

Agonists postsynaptic striatal D2 1.5 mg TID; Ropinirole: 0.25 mg delay motor fluctuations.

• Pramipexole and D3 receptors. TID to 8 mg TID; Rotigotine: • ADVERSE: IMPULSE CONTROL DISORDERS (15-20%),

Ropinirole 2 mg/24h patch up to 8 mg/24h. sudden daytime sleep attacks, orthostasis.

• Rotigotine (Patch)

MAO-B Inhibitors Irreversibly inhibits Rasagiline: 0.5 to 1 mg daily; • Modest symptomatic motor benefit;

• Rasagiline monoamine oxidase-B, Selegiline: 5 mg BID (with often used as initial monotherapy in mild disease.

• Selegiline blocking central dopamine breakfast and lunch). • Insomnia (selegiline metabolizes to amphetamine);

metabolism. caution with potent serotonergic agents.

COMT Inhibitors Inhibits catechol-O-methyl- Entacapone: 200 mg co-administered • ONLY effective when co-administered with levodopa.

• Entacapone transferase, blocking with each levodopa dose • Prolongs levodopa half-life; used to manage

peripheral conversion of (up to 8 times daily). "wearing-off" motor fluctuations.

levodopa to 3-OMD. • Harmless orange-brown urine discoloration.

NMDA Receptor Uncompetitive NMDA receptor 100 mg PO BID to TID; • Specifically reduces LEVODOPA-INDUCED

Antagonist antagonist; stimulates extended-release formulations DYSKINESIAS without worsening parkinsonism.

• Amantadine dopamine release/synthesis. available. • Livedo reticularis (lace-like violaceous skin),

ankle edema, confusion, hallucinations.

Anticholinergics Blocks striatal muscarinic 0.5 to 2 mg PO TID • Useful for prominent resting tremor in

Trihexyphenidyl acetylcholine receptors. (titrate very slowly). younger patients (<60 years).

• Benztropine • AVOID IN ELDERLY: triggers severe delirium,

urinary retention, dry mouth, blurred vision.

1. Carbidopa / Levodopa (Sinemet)

Pharmacological Mechanism : Levodopa is the metabolic precursor to dopamine. Unlike dopamine, levodopa crosses the blood-brain barrier via large neutral amino acid transporters (LNAA). Carbidopa is a peripheral dopa-decarboxylase inhibitor that does not cross the blood-brain barrier . By preventing peripheral decarboxylation of levodopa into dopamine in the gut and systemic circulation, carbidopa increases brain levodopa delivery from 1% to over 10% and eliminates peripheral dopamine toxicity (severe nausea, vomiting, orthostatic hypotension, cardiac arrhythmias). A minimum of 75 to 100 mg of carbidopa per day is required to saturate peripheral enzymes.

Dietary Competition : Levodopa competes with dietary neutral amino acids for absorption across the intestinal mucosa and transport across the blood-brain barrier. Patients with advanced fluctuations should take levodopa 30 to 60 minutes before meals or avoid high-protein meals during the day.

Long-Term Motor Complications : After 5 to 10 years of levodopa therapy, >50% of patients develop disabling motor complications:

"Wearing-Off" (End-of-Dose Deterioration) : The clinical benefit of a levodopa dose shortens from 4-6 hours down to 2-3 hours, with motor parkinsonism re-emerging before the next scheduled dose. Management : Increase dosing frequency (fractionation), switch to extended-release formulations, or add a COMT inhibitor (entacapone) or MAO-B inhibitor (rasagiline) to prolong levodopa half-life.

Levodopa-Induced Dyskinesias (LID) : Involuntary choreic, athetoid, or ballismic movements occurring at peak plasma levodopa levels. Management : Reduce individual levodopa doses while increasing frequency, or add Amantadine (the only drug specifically approved for peak-dose dyskinesia).

2. Dopamine Agonists & The Warning on Impulse Control Disorders

Role : Non-ergot dopamine agonists directly stimulate striatal D2 and D3 receptors. They have longer half-lives than levodopa, providing more continuous dopaminergic stimulation. In patients <60 years of age, initial monotherapy with pramipexole or ropinirole is often considered to postpone the onset of levodopa-induced dyskinesias.

Impulse Control Disorders (ICDs) : Up to 15% to 20% of patients taking dopamine agonists develop severe, destructive impulse control disorders due to excessive stimulation of dopamine D3 receptors localized to the ventral striatum (nucleus accumbens) and mesolimbic reward pathways. Behaviors include pathological gambling, hypersexuality, compulsive shopping/spending, and binge eating . Patients frequently conceal these behaviors out of shame. Clinicians must specifically inquire about financial, sexual, and eating habits at every visit. When identified, the dopamine agonist must be slowly tapered to avoid Dopamine Agonist Withdrawal Syndrome (DAWS) (profound dysphoria, anxiety, suicidal ideation) while substituting levodopa.

Sudden Daytime Sleep Attacks : Dopamine agonists can induce irresistible, sudden somnolence without warning while operating machinery or driving; patients must be cautioned accordingly.

Essential Tremor: Clinical Characteristics, Genetics & Pathophysiology

Essential Tremor (ET) is the most prevalent movement disorder encountered in clinical medicine, affecting approximately 4% to 5% of adults aged >65 years. More than 50% of patients report a positive family history with an autosomal dominant pattern of inheritance with variable penetrance ("familial tremor"). Pathophysiologically, ET is considered an olivocerebellar network disorder, characterized by abnormal rhythmic oscillation in the cerebello-thalamo-cortical circuit. DIFFERENTIAL DIAGNOSIS OF COMMONLY ENCOUNTERED TREMORS

Feature Parkinsonian Tremor Essential Tremor (ET) Intention / Cerebellar Tremor

═══════════════════════════════════════════════════════════════════════════════════════════════════════════════════════

Tremor Frequency 4 to 6 Hz (Slow) 8 to 12 Hz (Rapid) 3 to 5 Hz (Slow, irregular)

───────────────────────────────────────────────────────────────────────────────────────────────────────────────────

Primary State RESTING tremor; limb fully ACTION tremor; kinetic (during INTENTION tremor; absent at rest;
supported against gravity purposeful goal-directed tasks) dramatically worsens as limb
and POSTURAL (arms outstretched) approaches the visual target

Symmetry ASYMMETRIC onset (one hand/foot) BILATERAL, SYMMETRICAL onset Variable; usually unilateral or
(both hands/arms) ipsilateral to cerebellar lesion

Body Regions Hands, feet, jaw, lips; Hands, wrists, HEAD (titubation), Extremities; associated with
Involved SPARES THE HEAD AND VOICE and VOCAL CORDS; SPARES LEGS dysmetria, dysdiadochokinesia

Response to None MARKED TEMPORARY REDUCTION None
Ethanol in tremor amplitude

Associated Signs Bradykinesia, rigidity, masked Isolated tremor; NO rigidity, Gait ataxia, nystagmus, dysarthria,

facies, shuffling festinating NO bradykinesia, NO masked past-pointing on finger-to-nose
gait, loss of arm swing facies (pure kinetic syndrome)

Clinical Presentation & The Alcohol Pearl

The tremor is an 8 to 12 Hz postural and kinetic action tremor . It is absent at complete rest. It manifests when the patient holds the upper extremities outstretched against gravity (postural tremor) or performs goal-directed movements (kinetic tremor)—such as drinking soup from a spoon, bringing a cup of water to the lips, buttoning a shirt, or drawing an Archimedes spiral.

Head involvement is frequent, presenting as a rhythmic vertical ("yes-yes") or horizontal ("no-no") titubation .

Vocal involvement manifests as a tremulous, wavering, quavering voice.

The Alcohol Phenomenon : Up to 60% to 70% of patients experience a dramatic, transient (1-2 hour) reduction in tremor amplitude after consuming a small amount of ethanol (e.g., one glass of wine or beer). Ethanol enhances central GABAergic inhibition within the olivocerebellar circuit. While pathognomonic, self-medication with alcohol carries a risk of secondary alcohol use disorder.

Evidence-Based Pharmacotherapy & Interventional Therapies for Essential Tremor

Pharmacotherapy is indicated when the tremor produces functional impairment in occupational tasks, self-care, or social interactions.

1. First-Line Pharmacotherapies

Propranolol : A non-selective beta-adrenergic blocker. Dosage starts at 40 mg daily (immediate-release divided BID or long-acting ER 60-80 mg daily), titrated up to 120 to 320 mg daily. It suppresses peripheral beta-2 receptors in muscle spindles.

Contraindications : Symptomatic bradycardia, second- or third-degree AV block, decompensated heart failure, and active asthma or severe bronchospastic COPD .

Primidone : An antiepileptic barbiturate prodrug metabolized to phenobarbital and phenylethylmalonamide (PEMA). Dosage starts extremely low at 12.5 to 25 mg PO at bedtime (to prevent acute toxic first-dose vertigo, nausea, sedation, and ataxia), then slowly escalated weekly up to a target maintenance of 50 to 250 mg PO three times daily (max 750 mg/day). Equiefficacious to propranolol.

Combination Therapy : In patients with severe or refractory tremor, propranolol and primidone can be combined synergistically.

2. Second-Line Therapies

Topiramate (100 to 400 mg daily), Gabapentin (300 to 1800 mg daily in divided doses), or Alprazolam (low-dose benzodiazepine, reserved for high-anxiety performance situations due to dependence risk).

3. Advanced Interventional & Surgical Therapies

Deep Brain Stimulation (DBS) : High-frequency electrical stimulation of the ventral intermediate (VIM) nucleus of the thalamus provides up to 80% tremor suppression in severe, medication-refractory, disabling essential tremor.

MRI-Guided Focused Ultrasound (MRgFUS) : Non-invasive, incisionless thermal ablation targeting the unilateral VIM thalamic nucleus using high-intensity focused ultrasound beams through the intact cranium under real-time thermal MRI guidance.